AstraZeneca’s experimental COVID-19 vaccine is probably the world’s leading candidate and most advanced in terms of development, the World Health Organization’s (WHO) chief scientist said.
Molecular Partners aims to test a COVID-19 drug candidate on people during 2020, Chief Executive Patrick Amstutz said, as the Swiss company hopes that project will help it recover from the failure of the eye drug abicipar.
Sosei Group entered a discovery collaboration and licensing deal with AbbVie, initially focused on inflammatory and autoimmune diseases.
Light-activated CRISPR technology edits genes more precisely and faster than the more standard chemical methods, and enables “super-fast” DNA repair, according to research from Johns Hopkins University School of Medicine.
Shares of Fulcrum Therapeutics were up more than 14 percent after the company announced plans tol begin the Phase LOSVID III study to assess losmapimod as a potential treatment of COVID-19.
New information released by GlobalData showed that there are now more than 718 pipeline drugs associated with COVID-19.
AstraZeneca signed a tenth supply-and-manufacturing deal for the company’s experimental COVID-19 vaccine with a Scotland-backed firm as the British drugmaker ramps up efforts for wider trials of the potential treatment.
Thermo Fisher Scientific and Daiichi Sankyo have partnered to co-develop a companion diagnostic device for patients who have non-small cell lung cancer (NSCLC).
Myovant announced topline results from SPIRIT 1, the second Phase III trial of once-daily relugolix combination therapy in women with pain linked with endometriosis.
The U.S. Food and Drug Administration greenlit Karyopharm Therapeutics’ Xpovio (selinexor) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) under accelerated approval.
